Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of EG12014 vs Herceptin in Healthy Volunteers
NCT03180242Phase 1Completed
- Sponsor
- EirGenix
- Start
- Mar 2016
- Primary completion
- Aug 2016
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
01
Overview
Phase 1, randomised, double-blind trial of trastuzumab biosimilar EG12014 in HER2-positive breast cancer and gastric cancer (GC) (3 arms), sponsored by EirGenix. Primary endpoint: Area under the concentration/time curve from time 0 extrapolated to infinity at 70 days. Started Mar 2016; status: completed.
02
Drugs
trastuzumab biosimilar EG12014
03
Conditions
HER2-positive breast cancergastric cancer (GC)
Beyond the preview
Go deeper on NCT03180242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03180242.